ArticleJournal of neuro-oncology2025
Incidence and survival of adult central nervous system tumors in the Veneto region: a population-based registry study (2016-2020).
Article in Journal of neuro-oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Incidence and Survival of Central Nervous System Tumors in Reunion Island: A Population-Based Study.Neuroepidemiology · 2026Article
- Real-World Treatment Pathways of Adult Patients with Glioblastoma and Other CNS Tumors: A Population-Based Registry Study.Current oncology (Toronto, Ont.) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeCentral nervous system (CNS) tumors represent a heterogeneous group of neoplasms with significant clinical impact and variable prognosis. Despite the relatively low incidence, they account for considerable morbidity and mortality. In Italy, population-based data on incidence and survival by histological subtype and tumor grade remain limited, particularly for rarer CNS tumor entities.
methodsWe conducted a retrospective population-based study using data from the Veneto Cancer Registry, including adults diagnosed with CNS tumors between 2016 and 2020. A dedicated text-mining algorithm was applied to pathology reports to extract tumor grade. Tumors were categorized into six main histological groups. We estimated incidence rates, relative survival, and 5-year conditional relative survival, stratified by sex, age, tumor type, and grade.
resultsA total of 1,636 incident CNS tumors with confirmed histopathology and intermediate to high-grade behavior were identified. Glioblastoma was the most frequent subtype (64.6%), followed by grade 2-3 meningiomas (18.2%) and astrocytomas (9.4%). The overall crude incidence was 8.0 per 100,000, higher in males (9.5) than females (6.6). Five-year relative survival varied substantially by tumor type and grade: glioblastoma had the poorest outcome (5.7%), while grade 2-3 ependymomas and oligodendrogliomas showed favorable prognosis (87.7% and 82.0%, respectively). Conditional 5-year survival after surviving one year remained low for glioblastoma (11.0%) but exceeded 85% for most lower-grade tumors.
conclusionOur findings underscore the prognostic relevance of tumor grade and histology, supporting the need for tailored clinical strategies, molecular diagnostics, and the development of innovative therapies for informed healthcare planning and resource allocation.
Indexed as
Identifiers
41091233What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.